A new trading day began on Friday, with Astrazeneca plc ADR (NASDAQ: AZN) stock price up 0.63% from the previous day of trading, before settling in for the closing price of $67.20. AZN’s price has ranged from $60.47 to $87.68 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 16.24%. Meanwhile, its annual earnings per share averaged 13.85%. With a float of $3.10 billion, this company’s outstanding shares have now reached $3.10 billion.
Considering the fact that the conglomerate employs 89900 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 77.2%, operating margin of 18.41%, and the pretax margin is 15.5%.
Astrazeneca plc ADR (AZN) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Drug Manufacturers – General Industry. The insider ownership of Astrazeneca plc ADR is 0.03%, while institutional ownership is 15.79%.
Astrazeneca plc ADR (AZN) Recent Fiscal highlights
In its latest quarterly report, released on 9/30/2024, the company reported earnings of 0.73 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of 1.11 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 13.85% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.00% during the next five years compared to 17.72% growth over the previous five years of trading.
Astrazeneca plc ADR (NASDAQ: AZN) Trading Performance Indicators
Here are Astrazeneca plc ADR’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 0.71. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 4.09. Likewise, its price to free cash flow for the trailing twelve months is 21.07.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.08, a number that is poised to hit 1.06 in the next quarter and is forecasted to reach 4.72 in one year’s time.
Technical Analysis of Astrazeneca plc ADR (AZN)
Compared to the last year’s volume of 5.31 million, its volume of 5.14 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 97.58%. Additionally, its Average True Range was 1.34.
During the past 100 days, Astrazeneca plc ADR’s (AZN) raw stochastic average was set at 19.54%, which indicates a significant decrease from 97.99% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 18.39% in the past 14 days, which was lower than the 22.94% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $72.49, while its 200-day Moving Average is $74.81. Nevertheless, the first resistance level for the watch stands at $67.85 in the near term. At $68.07, the stock is likely to face the second major resistance level. The third major resistance level sits at $68.43. If the price goes on to break the first support level at $67.27, it is likely to go to the next support level at $66.91. Now, if the price goes above the second support level, the third support stands at $66.69.
Astrazeneca plc ADR (NASDAQ: AZN) Key Stats
With a market capitalization of 209.66 billion, the company has a total of 3,100,608K Shares Outstanding. Currently, annual sales are 45,811 M while annual income is 5,955 M. The company’s previous quarter sales were 13,565 M while its latest quarter income was 1,429 M.
